The ORange intraoperative wavefront aberrometer provides cataract surgeons with on-demand measurements so that they can make adjustments on the table, to help ensure their patients achieve the refractive outcome they expect.
WaveTec CEO Tom Frinzi said the infusion of capital will allow them to expand commercialization and adoption of ORange, grow infrastructure and further demonstrate clinical efficacy as they bring Custom Cataract technology to many more surgeons and their patients.
The Series D financing was led by existing investor Versant Ventures, with participation from existing investors Accuitive Medical Ventures and De Novo Ventures.
New investor Gund Investment Corporation also participated in the funding.
